Introduction
Little is known the anti-nociceptive role of cyclin-dependent kinase 5 (Cdk5) which previously belongs to serine/threonine kinase. Wang et al. (2004) , firstly reported that the morphine tolerance development can be significantly attenuated by intrathecal administration of Cdk5 inhibitor roscovitine, which has laid down the important foundation for further study of Cdk5 mediating the pain hypersensitivity. Latter studies indicated that Cdk5 mainly mediated thermal hyperalgesia induced by inflammation (Pareek et al., 2006 (Pareek et al., , 2007 Yang et al., 2007; Utreras et al., 2011; Zhang et al., 2012a Zhang et al., , 2012b Xing et al., 2012; Zhang et al., 2012a Zhang et al., , 2012b . -In contrast to other Cdks, regulation of Cdk5 activity is mediated by specific activator proteins (p35 or p39) or their variants (p25 or p30) (Zheng et al., 1998) . Cdk5 in the dorsal root ganglion (DRG) of rats is an upstream modulator of complete Freund's adjuvant (CFA)-induced thermal hyperalgesia via its effects on membrane trafficking of the transient receptor potential channel and phosphorylation of the vanilloid receptor 1 (Xing et al., 2012; Pareek et al., 2007) . And thus, the activities of Cdk5 and p35 were significantly increased upon peripheral injection of CFA, whereas Cdk5 activity and associated thermal hyperalgesia in this model were both inhibited by Cdk5/p35 knockdown or by intrathecal administration of roscovitine, a specific inhibitor of Cdk5 . Nevertheless, the mechanisms underlying mediation of inflammation-induced thermal hyperalgesia by Cdk5 remain poorly understood.
In addition to its function in inflammation pain, Cdk5 has been implicated in the pathogenesis of Alzheimer's disease via its action as a key upstream regulator of p38. In this conceptual model, pharmacological inhibition of Cdk5 prevented p38 activation in neurons upon stimulation with the excitatory amino acid glutamate (Chang et al., 2010) . In particular, roscovitine significantly inhibited the expression of increased p-p38 protein levels in microglia following exposure to glutamate. The mitogen-activated protein kinase (MAPK) family includes extracellular signal-regulated kinase (ERK), p38 MAPK, and c-Jun N-terminal kinase, and ERK and p38 MAPK together are thought to be involved in modulating inflammation-induced pain hyperalgesia in the DRG and spinal cord (Piao et al., 2006; Boyle et al., 2006; Ji et al., 2002) ; however, Yang et al. (2007) failed to examine an obvious role for ERK1/2 in mediating the thermal hyperalgesia mediated by Cdk5 in the CFA-induced inflammatory pain model. Based on the general findings of a linkage between Cdk5 and activated p38 in modulating inflammatory pain, in
the present study, we tested the hypothesis that Cdk5 mediated pain hypersensitivity via the p38 MAPK signaling pathway.
Results
2.1. Activated p38 in the spinal cord was restricted entirely to microglia and neurons following plantar injection of CFA In different inflammatory pain models, the activated p38 MAPK functions in mediating the cell signaling pathway in glial cells and neurons. Based on the close association between p38 MAPK and glial cells and neurons, we characterized their colocalization using double-immunofluorescence ( Fig. 1 ). In our model, results of double immunofluorescence analysis demonstrated that p-p38 was not colocalized with GFAP in astrocytes in L4 and L5 at day 1 post-CFA injection ( Fig. 1A-D) . In contrast, this result indicated complete colocalization of p-p38 and OX-42 in microglia in dorsal horn of the spinal cord at days 1 and 3 ( Fig. 1I-P) . We also observed that p-p38 weakly colocalized with NeuN, a neuronal marker, in neurons (in dorsal horn of the spinal cord) at day 1 post-CFA injection ( Fig. 1E-H ).
2.2.
Activated p35 in the spinal cord was restricted entirely to microglia and neurons in the spinal cord at L4/L5 following plantar injection of CFA As the activator of Cdk5, p35 functions in activating Cdk5 and mediating the signaling pathway of inflammatory pain. We observed the colocalization between p35 and glial cells and neurons using double immunofluorescence. Our results demonstrated that p35 and NeuN colocalized with Cdk5 in neurons in dorsal horn of the spinal cord at day 1 post-CFA injection ( Fig. 2A-H) ; however, p35 was not colocalized with GFAP in astrocytes in the L4 and L5 spinal cord in our model (Fig. 2I-L) . In contrast, complete colocalization of p35 and OX-42 was observed in microglial cells in dorsal horn of the spinal cord at days 1 and 3 post-CFA injection (Fig. 2M-T) . This finding suggests that besides the neuronal signaling pathway, Cdk5/p35 mediated the inflammatory pain via the microglia signaling pathway rather than the astrocytic pathway.
2.3.
Thermal hyperalgesia induced by intraplantar CFA injection was significantly reversed by intrathecal administration of either roscovitine or SB203580
It is well known that thermal hyperalgesia was closely associated with inflammatory pain. In our study, we observed the changes in nociceptive behavior following CFA peripheral injection from 1 day to 5 days by measuring thermal PWLs. Additionally, we tested effects of both of roscovitine (a Cdk5 inhibitor) and SB203580 (a p38 inhibitor) on the thermal PWLs, respectively. The peak of thermal hyperalgesia presented at 1 day following injection of CFA into rat ipsilateral hind paws and lasted for 5 days. The mean thermal PWL threshold (seconds) of ipsilateral hind paws was significantly reduced post-CFA injection from days 1 to 5 (day 1, 2.3270.63 s; day 3, 4.4270.72 s; day 5, 5.6870.82 s) compared to that in the contralateral hind paws injected with saline in the same group during the same time span (day 1, 10.7371.54 s (s); day 3, 11.4370.71 s; day 5, 11.0370.73 s, nn po0.01, Fig. 3A , n¼ 6); however, no obvious change was observed between the ipsilateral and contralateral hind paws of the DMSO control group challenging with saline (p40.05, Fig. 3A, n¼6) . Additionally, the decreased average ipsilateral paw PWL thresholds were significantly reversed by pre-treatments with roscovitine or SB203580 30 min prior to CFA injection from days 1 to 5 (day 1, 5.2670.98 s; day 3, 6.4270.36 s; day 5, 7.2370.32 s) and (day 1, 4.7570.74 s; day 3, 7.1270.27 s; . p-p38 was colocalized with OX-42 in microglia 1 and 3 days post-CFA injection (P, white arrow head) (I-P). p-p38 was weakly colocalized with NeuN in neurons 1 day post-CFA injection (H, white arrow head) (E-H). (n ¼ 3 per group, magnification X40, scale bar¼20 lm). 
2.4.
OX-42 upregulation in rat spinal cords following CFA challenge was reduced by pretreatment with roscovitine Based on the duration of thermal hyperalgesia induced by CFA injection, in the present study, we observed the changes in protein expression of OX-42 over time using Western blot analysis. The ipsilateral tissues of the L4/L5 segment of the spinal cord dorsal horn of rats were removed and used for Western blot analysis 1 to 7 days following CFA injection. Results showed that OX-42 was significantly upregulated post-intraplantar injection with CFA between days 1 and 5 (day 1, 1.3470.06; day 3, 1.4970.14; day 5, 1.3170.27) and decreased (0.6770.19) by day 7 compared to the control group (0.6470.01, n po0.05, Fig. 4A , n¼ 3). Furthermore, increased levels of OX-42 were significantly decreased by administration of roscovitine between days 1 and 3 (0.5970.03 at day 1, 0.3970.02 at day 3) compared to expression levels observed in the DMSO group (1.0470.02 at day 1, 0.9370.06 at day 3, n po0.05, Fig. 4B , n¼ 3).
2.5.
p-p38 upregulation in rat spinal cords following CFA challenge was reduced by pretreatment with roscovitine
To examine the changes in p-p38 protein expression in our model, the ipsilateral tissues of the L4/L5 segment from the dorsal horn of the spinal cord were dissected. Western blot analysis was performed from 1 to 7 days following CFA injection. The results showed that p-p38 was significantly upregulated post-CFA injection from days 1 to 5 (day 1, 1.0070.03; day 3, 1.1970.05; day 5, 1.327033) and decreased (0.6770.19) by day 7 compared to the control group (0.6370.15, n po0.05, Fig. 5A , n ¼3). Additionally, increased levels of p-p38 induced by CFA were significantly decreased by administration of roscovitine between days 1 and 3 (0.5770.05 at day 1; 0.4870.00 at day 3) compared to 
2.6.
TNF-α upregulation in rat spinal cords following CFA challenge was reduced by pre-treatment with roscovitine
Given that TNF-α functions in mediating inflammatory pain via p-p38 (Hanisch, 2002) , we examined whether Cdk5 mediated the thermal hyperalgesia via the TNF-α pathway. The ipsilateral tissues of the L4/L5 segment of the spinal cord dorsal horn were removed and used for ELISA 1-7 days following CFA injection. We found that the level of TNF-α was significantly increased from day 1 to 3 (day 1, 0.7870.10; day 3, 0.9870.12, day 5, 0. 0.7270.11) and decreased (0.4170.11) by day 7 compared with the control group (0.3370.10, n po0.05, Fig. 6A , n¼ 6). Furthermore, results showed that the increased TNF-α levels were remarkably reduced by roscovitine at days 1 and 3 following CFA injection between 1 day and 3 day (0.3870.11 at day 1; 0.4870.13 at day 3) compared to the expression levels observed in the DMSO group (0.8770.11 at day 1; 1.0870.12 at day 3, n po0.05, Fig. 6B, n¼6) . Collectively, these data suggest that Cdk5 mediated the thermal hyperalgesia induced by CFA injection from 1d to 5 days partly by blocking the transferring pathway between pp38 and TNF-α (Fig. 7) .
Discussion
In the present study, our results showed that the maximum thermal hyperalgesia induced by peripheral injection CFA occurred at 1 day following injection and decreased until 5 days. In our model, immune-positive expression of p-p38 was prominently distributed in the microglia and was colocalized with OX-42 in the dorsal horn of the spinal cord and weakly distributed in neurons 1 day post-CFA injection.
Additionally, p35 was highly colocalized with OX-42 at days 1 and 3 post-CFA injection. In contrast, colocalization of p35 and GFAP, a marker of activated astrocytes, was not observed in the spinal cord at the same time point. The
Fig. 5 -p-p38 protein levels were significantly upregulated in spinal cord dorsal horns, but the increase was reversed by roscovitine. Compared to the control group, p-p38 expression was significantly increased from day 1 to day 3 post-CFA injection (*po0.05) (A). Increased p-p38 protein levels were decreased by intrathecal injection of roscovitine compared to the DMSO-treated controls between days 1 and 3 postCFA injection (*po0.05) (B).
Fig. 6 -TNF-α release was remarkably increased in spinal cord dorsal horns, but the increase was reversed by roscovitine. Compared to the control group, p-p38 expression was significantly increased from day 1 to 5 post-CFA injection. (*po0.05)(A). Increased TNF-α levels were clearly decreased by intrathecal injection of roscovitine compared to DMSO-treated controls between days 1and 3 postCFA injection (*po0.05) (B). (n ¼ 6/group).
principal conclusion of this study is that Cdk5, which is the upstream regulator of phosphorylation of p38 and TNF-α, mediates thermal hyperalgesia induced by peripheral injection of CFA. Unlike other Cdks, Cdk5 kinase activity is generally thought to be associated with its activator p35, which is mainly expressed in neurons rather than microglia or astrocytes (Zheng et al., 1998) . Our present results showed p35 expression in neurons as well as in microglia at days 1 and 3 post-CFA injection, suggesting that Cdk5/ p35 may mediate thermal hyperalgesia induced by peripheral injection of CFA between neurons and activated microglial cells. Meanwhile, the experimental data indicated that p-p38 and p35 were weakly colocalized with NeuN, and that the thermal hyperalgesia mediated by Cdk5 in CFA-induced inflammatory pain was not mainly mediated via p-p38 interacting with the neuron system. Previous studies demonstrated that glial cells (microglia and astrocytes) in the central nervous system function in mediating peripheral insults . As determined by upregulation of glial cell markers, both microglia and astrocytes are activated when a variety of peripheral nerve injuries occur, including nerve transection, ligation, crushing, and chemical insult (Zhuang et al., 2007; Garrison et al., 1991) . Results reported by other laboratories have demonstrated that the protein levels of OX-42 and GFAP are significantly upregulated in inflammatory and pathological pain models due to the activation of both microglia and astrocytes Zhuang et al., 2007; Garrison et al., 1991; Kalla et al., 2001; Fu et al., 1999; Svensson et al., 2003) . In the present study, p-p38 was exclusively colocalized with OX-42 in the dorsal horn on the side that was injected with CFA. Hanisch (2002) showed that activated microglia are a source of multiple cytokines, including interleuin-1β (IL-1β), IL-6, and tumor necrosis factor-a (TNF-α). These cytokines are likely to contribute to different features of pathological pain, although their role within the spinal cord has not been fully explored (DeLeo and Yezierski, 2001) . A recent study demonstrated that reveratrol, an inhibitor of Cdk5, with effects similar to the compounds used in the present study, regulated the p35 promoter activity in PC12 cells and DRG neurons and blocked the activation of p35 induced by TNF-α, such that subsequent Cdk5 kinase activation was inhibited (Utreras et al., 2011) , and thus, we proposed that roscovitine might reverse the thermal hyperalgesia induced by peripheral injection of CFA by inhibiting secretion of TNF-α trigged by p-p38. The results of our experiments indicated that the release of TNF-α was significantly increased 1 and 3 days post-CFA injection and that an increase in TNF-α were remarkably reduced by pretreatment with roscovitine. These findings indicate that the p-p38 and TNF-a signaling pathways were involved in the inflammation mediated by Cdk5. While concurring with some earlier findings, our results showed that p35 was exclusively colocalized with OX-42 in the spinal cord, which seemed to be at odds with the previous studies, demonstrating that p35 was exclusively colocalized with GFAP in the hippocampal CA1 zone . This discrepancy between the two experiments may be due to the different models of experimental treatments; however, the implication is that Cdk5/p35 is indeed activated in microglia and astrocytes but only under appropriate conditions. A previous study demonstrated that intrathecal injection of roscovitine markedly attenuated thermal hyperalgesia induced by peripheral injection of CFA by inhibiting Cdk5 kinase activity . The present study revealed that the inhibition of p38 by SB20358 and Cdk5 inhibition by roscovitine significantly reversed the lowered threshold of thermal hyperalgesia induced by CFA from 1 d to 5 d following CFA injection. Furthermore, p-p38 protein levels in the dorsal horn were obviously increased between days 1 and 5 post-CFA injection, but this increase was reversed by intrathecal injection of the Cdk5 inhibitor roscovitine, suggesting that inhibition of Cdk5 kinase activity, as the upstream regulator of p38, reduced the nociceptive behavior by inhibiting the p-p38 signaling pathway, however, previous studies in the CFA-induced inflammatory pain model showed that roscovitine at a dose of 100 mg had no obvious effects on expression of p-Erk1/2, a kinase belonging to the MAPK family . Insofar as p38 MAPK and ERK belong to the same family of MAPKs, the mechanism by which ERK mediates inflammatory pain in its capacity as an extracellular signal-regulated kinase must be different from that of the intracellular kinase p38 (Han et al., 2012) . The kinase product p-p38 serves to transduct the pain message from nuclei of neurons and glial cells to an extracellular site. In contrast, the ERK signaling pathway mediates pain sensitization from extracellular sites to the nucleus of neurons and glial cells.
Considerable evidence shows that occurrence of pain sensitization entails various factors and alterations in both neurons and glial cells (microglia and astrocytes) rather than arising from a single factor or single cell population The elevated Cdk5 activity then increased p38 activity and the levels of TNF-α release in microglia in the spinal cord, ultimately, leading to pain hypersensitivity by Cdk5/p35-p38 dependent signaling pathway in microglia.
( McMahon et al., 2005; Scholz and Woolf, 2007; Milligan and Watkins, 2009 ). In the present study, p-p38 was weakly colocalized in the neurons of the spinal cord, demonstrating that p38 perhaps does not have a principle role in mediating the CFA-induced inflammatory pain in neurons.
We found that experimentally induced hyperalgesia was associated with increased protein expression of OX-42 in the lumbar cord. Intrathecal injection of roscovitine significantly reduced the protein level of OX-42 at days 1 and 3 post-CFA application to the plantar paw. The thermal hyperalgesia development from 1 day to 5 days following CFA injection seemed not at odds with the changing of OX-42 protein expression. We similarly found that increased protein levels of p-p38 and TNF-α were significantly reversed by intrathecal injection of roscovitine, which suggested that inhibition of Cdk5 kinase activity by roscovitine inhibited the activation of microglia in the CFA-induced inflammatory pain model.
Although the activities of Cdc2, Cdk2, and Cdk5 kinases are all inhibited by roscovitine (Meijer et al., 1997) , our previous findings suggest that effects of roscovitine are confined mainly to Cdk5 activity rather than Cdks in adult rats (Zhang et al., 2012a (Zhang et al., , 2012b . Consequently, we conclude that spinal administration of roscovitine mainly inhibited activation of microglia and the p-p38 and TNF-a signaling pathway by inhibiting Cdk5 activity. Additionally, the suppression of increased p-p38 protein expression by roscovitine at days 1 and 3 and the persistence of attenuation of thermal hyperalgesia in our model for over 5 days suggest that p-p38 is partly involved in the thermal hyperalgesia mediated by Cdk5. Meanwhile, due to the fact that the overall activities of Cdk5 and p-p38 were not inhibited by roscovitine and SB20358 and other possible cell signaling pathways involved, the thermal hyperalgesia by CFA injection cannot be utterly inhibited by roscovitine and SB20358 as we expected.Future studies are required to elucidate the mechanism of action in the gene based model including Cdk5 and p-p38 gene knockout. Taken together, we hypothesize that pathway of Cdk5-mediated inflammatory pain induced by CFA may be that the nociception caused by CFA injection leads to an increase in Cdk5/p35 activity in the spinal cord and the elevated Cdk5 activity, then increases p38 activity and the levels of TNF-a release in microglia in spinal cord, ultimately resulting in pain hypersensitivity by Cdk5/p35-p38 dependent signaling pathway in microglia, which is a possible demonstration of how the enhanced expression of OX-42, p-p38 MAPK and TNF-a was reduced by roscovitine as well.
Conclusion
Our study demonstrated that p35 was colocalized with OX-42 in the dorsal horn of the spinal cord in rats with CFA-induced inflammation. Spinal administration of the Cdk5 inhibitors roscovitine or SB20358 markedly alleviated the CFA-induced thermal hyperalgesia in a behavioral assay. Increased protein levels of OX-42, p-p38 MAPK and TNF-a in the spinal cord were significantly reversed by intrathecal administration of roscovitine, suggesting that Cdk5, as the upstream regulator of p38, functions in inducing and developing the early stage of chronic inflammatory pain. The results of our study indicate that the p38 signaling pathway contributes to inflammation-induced thermal hyperalgesia mediated by Cdk5 in rats. Consequently, we proposed that breaking down the association between Cdk5 and the p38 signaling pathway may present a potential therapeutic target for diminishing inflammatory pain.
Experimental procedures

Animals
One hundred twenty adult male Sprague-Dawley rats (200-250 g) obtained from the Animal Center of Nanjing Medical University were used in our experiments. All surgical and experimental procedures were reviewed and approved by the Committee of Animal Use for Research and Education of Nanjing Medical University and were in accordance with the guidelines established by the Committee on Ethical Issues of the International Association for the Study of Pain (Charlton, 1995) . Rats were housed at a temperature of 2272 1C under a standard 12/12 h light/dark cycle and had free access to food and water. The animals were allowed to acclimate to the housing facilities for 1 week prior to beginning the experiments, and all efforts were made to minimize stress and the number of animals used.
CFA administration
The first experiment was conducted to test the effects of CFA on thermal hyperalgesia in rats. CFA (100 ml, Sigma, St. Louis, MO) was injected into the plantar surface of the left hind paw of six rats and saline100 ml was injected into the right hind paw of at the same group. As a control, saline (100 ml) was injected into the plantar surface of the left hind paw of six rats and the right hind paw of another six rats. Behavioral analysis and cell testing were performed as described below.
Catheter insertion and drug administration
Drugs were delivered by intrathecal injection as previously described, but with a slight modification (Yaksh and Rudy, 1976) . In brief, rats were anesthetized with pentobarbital (40 mg/kg i.p.) and a spinal catheter (PE-10: 0.28 mm i.d. and 0.61 mm o.d., Clay Adams, Parsippany, NJ, USA) was inserted between lumbar vertebrae 4 and 5 (L4 and L5). Following recovery from anesthesia and catheter insertion, verification of the proper placement of the catheter was confirmed by injecting 5 ml of 2% lidocaine flushed with 15 ml of saline; successful insertion of the catheter was confirmed if the rat presented with impairment of hind limb motor function for 10 s post-lidocaine administration. On the day of catheter insertion and for 4 days thereafter, rats received daily injections of saline vehicle in 10% DMSO, 100 mg of roscovitine (Sigma, St. Louis, MO, R7772) or 30 mg of SB203580 (Sigma S8307) (drugs dissolved in 10% DMSO), followed by flushing of the syringe with 15 ml of sterile saline. In this experiment, the CFA administration took place on the first day only at 30 min after the intrathecal injections. Each of the three treatment groups included 24 rats (six each for the right and left hind paw for the CFA and saline treatments).
Behavioral testing
Thermal hyperalgesia was quantified by measuring paw withdrawal latencies (PWLs) to radiant thermal stimulation as previously described (Hargreaves et al., 1988) . In brief, radiant thermal was directed to the plantar surface of each hind paw through a 1 mm thick glass plate. To avoid overthermaling the skin, exposure was terminated after a maximum of 20 s. The time between onset of the stimulus and the initiation of paw withdrawal was recorded as the thermal nociceptive latency period. Prior to the behavior test, rats were allowed to acclimate to the chamber for 30 min, and then the thermal stimulus was delivered sequentially to the ipsilateral and contralateral hind paws of the rats. PWLs were measured in triplicate trials 5 min apart for each paw at day 0, 1, 3, and 5 post-CFA or saline administration. The interval between PWL measurement of the right and left paws was 5 min. PWL measurements for rats in the CFA vs. saline test and the DMSO, roscovitine, and SB203580 experiment were taken in an identical manner.
Immunofluorescent staining
Animals were deeply anesthetized with sodium pentobarbital (4100 mg/kg i. 
Protein extraction and Western blot analysis
Tissues of spinal lumbar enlargements from unperfused animals from the respective treatment groups were rapidly removed and homogenized in ice-chilled lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1.5 mM MgCL 2 , 10% glycerol, 1% Trition X-100, 5 mM EGTA, 0.5 mg/ml leupetin, 1 mM PMSF, 1 mM Na 3 VO 4 , 10 mM NAF, and a proteinase inhibitor cocktail). Homogenates were centrifuged at 12,000 Â g for 15 min at 4 1C, and protein concentrations were determined using a BCA assay kit (Pierce, Rockland, IL, USA). Portions containing 30 mg of protein were separated by SDS-PAGE and transferred onto PVDF membranes. Post blocking was obtained by incubation with 1% BSA in TBST (50 mM Tris-HCl, pH 7.5, 150 mM, NaCl, 0.05% Tween 20) for 1 h at room temperature. The membranes were then incubated overnight at 4 1C with appropriate primary antibodies (anti-OX-42, 1:500, Abcam ab78457; anti-p-p38, 1:500, Cell Signaling). Membranes were washed for 15 min in TBST between all incubations. Blots were then incubated with a 1:1000 dilution of horseradish peroxidase-conjugated secondary antibody (goat anti-rabbit or -mouse, respectively) for 1.5 h at room temperature. Respective bands were visualized by incubation with enhanced chemiluminescence reagent (Boehringer Mannheim, Indianapolis, IN, USA) and exposure to X-ray film, which was developed and digitally analyzed using NIH Image software, version 1.60.
TNF-α enzyme-linked immunosorbant assay
Rats from the different treatment groups were euthanized by pentobarbital (4100 mg/kg i.p). Tissues derived from the L4/ L5 segment from the ipsilateral spinal cord dorsal horn of the left side were removed, weighed, and immediately homogenized in solution containing 50 mM Tris, pH 7.4, 150 mM NaCL, 1.5 mM MgCL2, 10% glycerol, 1% Trition X-100, 5 mm EGTA, 0.5 ug/ml leupetin, 1 mM PMSF, 1 mM Na3VO4, 10 mM NAF, and proteinase inhibitor cocktail. The TNF-levels (pg/mg protein) were determined using the Chemikine TNF-α kit following the protocol of the manufacturer.
Statistical analysis
